Citations

Mayo Clinic

Showing 10 of 108551 citations.

Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review
Luo, Jia , Florez, Narjust , Donnelly, Anjali, Lou, Yanyan , Lu, Kevin , Patrick, C. , Spira, Alexander I. , Ryan, Debra L., Husain, Hatim , Duma, Narjust , Florez, Narjust

JCO Precision Oncology | April 5, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.23.00644 | PMID 38579193 Get It

PURPOSE KRAS is the most commonly mutated driver oncogene in non–small cell lung cancer (NSCLC). Sotorasib and adagrasib, KRAS G12C inhibitors, have been granted accelerated US approval; however, hepatotoxicity is a common side effect with higher rates in patients treated with sotorasib proximal to checkpoint inhibitor (CPI) therapy. The aim of this study was to assess the feasibility and safety of adagrasib after discontinuation of sotorasib because of treatment-related grade 3 hepatotoxicity through real-world and clinical cases. METHODS Medical records from five patients treated in real-world settings were retrospectively reviewed. Patients had locally advanced or metastatic KRAS G12C -mutated NSCLC and received adagrasib after sotorasib in the absence of extracranial disease progression. Additional data were collected for 12 patients with KRAS G12C -mutated NSCLC enrolled in a phase Ib cohort of the KRYSTAL-1 study and previously treated with sotorasib. The end points associated with both drugs included timing and severity of hepatotoxicity, best overall response, and duration of therapy. RESULTS All patients were treated with CPIs followed by sotorasib (initiated 0-64 days after CPI). All five real-world patients experienced hepatotoxicity with sotorasib that led to treatment discontinuation, whereas none experienced treatment-related hepatotoxicity with subsequent adagrasib treatment. Three patients from KRYSTAL-1 transitioned from sotorasib to adagrasib because of hepatotoxicity; one experienced grade 3 ALT elevation on adagrasib that resolved with therapy interruption and dose reduction. CONCLUSION Adagrasib may have a distinct hepatotoxicity profile from sotorasib and is more easily combined with CPIs either sequentially or concurrently. These differences may be used to inform clinical decisions regarding an initial KRAS G12C inhibitor for patients who recently discontinued a CPI or experience hepatotoxicity on sotorasib.
Silicone cryogel skeletons enhance the survival and mechanical integrity of hydrogel-encapsulated cell therapies
Jeang, William J. , Bochenek, Matthew A. , Bose, Suman , Zhao, Yichao , Yang, Jiawei , Jiang, Alexis L., Langer, Róbert , Anderson, Daniel G. , Yang, Jiawei , Langer, Robert , Anderson, Daniel G , Wong, Bryan M.

Science Advances | April 5, 2024 | Volume: 10 | Issue: 14 | Pages: No page available

10.1126/sciadv.adk5949 | PMID 38578991 Get It

The transplantation of engineered cells that secrete therapeutic proteins presents a promising method for addressing a range of chronic diseases. However, hydrogels used to encase and protect non-autologous cells from immune rejection often suffer from poor mechanical properties, insufficient oxygenation, and fibrotic encapsulation. Here, we introduce a composite encapsulation system comprising an oxygen-permeable silicone cryogel skeleton, a hydrogel matrix, and a fibrosis-resistant polymer coating. Cryogel skeletons enhance the fracture toughness of conventional alginate hydrogels by 23-fold and oxygen diffusion by 2.8-fold, effectively mitigating both implant fracture and hypoxia of encapsulated cells. Composite implants containing xenogeneic cells engineered to secrete erythropoietin significantly outperform unsupported alginate implants in therapeutic delivery over 8 weeks in immunocompetent mice. By improving mechanical resiliency and sustaining denser cell populations, silicone cryogel skeletons enable more durable and miniaturized therapeutic implants.
Highly Sensitized Candidates Remain at Risk for Microvascular Inflammation Even When Donor-specific Antibody Is Avoided: A Matched Cohort Study
Balakrishnan, Suryanarayanan, Alexander, Mariam P., Cornell, Lynn D. , Kukla, Aleksandra , Agrawal, Amogh, Stegall, Mark, Cornell, Lynn , Agrawal, Amogh , Gandhi, Manish J. , Bentall, Andrew , Stegall, Mark D. , Schinstock, Carrie A.

Transplantation | April 5, 2024 | Volume: 108 | Issue: 9 | Pages: 1986-1993

10.1097/tp.0000000000005011 | PMID 38578704 Get It

Background. Microvascular inflammation (MVI) is a key feature of antibody-mediated rejection (AMR) among patients with HLA donor-specific antibody (DSA), but MVI at AMR thresholds (Banff glomerulitis [g] + peritubular capillaritis [ptc] score ≥ 2) without DSA has been increasingly recognized. We aimed to determine the incidence of MVI among highly sensitized kidney transplant recipients without DSA. Methods. We performed a single-center, retrospective, matched cohort study comparing outcomes of kidney transplant recipients with cPRA ≥90% with preexisting DSA (n = 49), cPRA ≥90% without preexisting DSA (n = 47), and matched controls with cPRA = 0 without preexisting DSA (n = 49). Controls were matched by age, donor type, and transplant date. Indication and surveillance biopsies combined with annual de novo DSA screening were obtained. Results. Kidney transplant recipients with a cPRA ≥90% and no evidence of preexisting or de novo DSA had a higher incidence of MVI (glomerulitis + peritubular capillaritis ≥ 2) than patients with cPRA = 0 [35% (17/49) versus 12% (6/49), P = 0.0003] over a median (interquartile range) follow-up of 5 (4–6) y posttransplant. Among this cPRA ≥90% group without DSA, MVI persisted in 54% of cases on follow-up biopsy (7/13), and 24% (4/13) of cases developed transplant glomerulopathy (Banff cg score > 0). Conclusions. Highly sensitized transplant recipients have a high incidence of persistent and progressive MVI, even without DSA. The mechanisms underlying these histologic features needs to be elucidated, but this information is important to consider when making decisions about transplantation among highly sensitized individuals.
A 10-year-old female with Cor triatriatum sinister (CTS): a rare case report and literature review from Syria
Sleiay, Mouhammmed, Sleiay, Bilal , Jawad, Ali , Hassan, Bassam , Masri, Mahmod, Stitieh, Youmna, Alokla, Abdulrahim Hamad, Mansour, Marah , Hussein, Bassam

Annals of Medicine & Surgery | April 5, 2024 | Volume: 86 | Issue: 9 | Pages: 5481-5485

10.1097/ms9.0000000000001991 | PMID 39239037 Get It

Introduction and importance: Cor triatriatum sinister (CTS) is an uncommon heterogeneous congenital cardiac defect that may manifest in adulthood when symptomatic blockage manifests due to a change in hemodynamic physiology or when a condition such as atrial fibrillation (AF) arises. The incidence of cor triatriatum with cardiomyopathy and congenital heart illness ranges from 0.1 to 0.4%. Case presentation: The Department of Cardiology examined a 10-year-old girl for a diastolic murmur. The patient’s medical history was ordinary, and no previously known co-morbid illnesses were present. Pneumonia was the patient’s original medical condition. A cardiac murmur was also discovered during the physical examination, and the patient was forwarded for more research. Physical examination revealed just a diastolic murmur, which was noteworthy. The patient’s care plan includes routine echocardiographic monitoring. Since the deformity was not clinically significant, surgical repair was not advised. Clinical discussion: It is unclear what caused this flaw. A full, incomplete, or fenestrated septum may be the result of the common pulmonary vein failing to merge with the left atrium during embryonic development. The existence of a fibromuscular membrane, which separates the left atrium (LA) into two chambers—the proximal chamber receiving the pulmonary veins (PVs) and the distal chamber contains the mitral valves and LA appendages defines the disease. Conclusion: The diagnostic procedure should be carried out in the optimal settings, however, in cases of frail health systems, employing accessible alternatives might help the early diagnosis. Early referral to a cardiologist is required in case of CTS suspicion.
Retain and Adapt: Online Sequential EEG Classification With Subject Shift
Duan, Tiehang , Wang, Zhenyi , Shen, Li , Doretto, Gianfranco , Adjeroh, Donald , Li, Fang , Tao, Cui , Tao, Cui , Li, Fang , Shen, Li

IEEE Transactions on Artificial Intelligence | April 5, 2024 | Volume: 5 | Issue: 9 | Pages: 4479-4492

10.1109/tai.2024.3385390 Get It

Posterior Cruciate Ligament Injury After Retrograde Nailing of Periprosthetic Distal Femur Fractures
Martinez, Frank A. , Yuan, Brandon J. , Yuan, Brandon , Martinez, Frank

JBJS Case Connector | April 5, 2024 | Volume: 14 | Issue: 2 | Pages: No page available

10.2106/jbjs.cc.23.00510 | PMID 38579021 Get It

Case: A 51-year-old man and 64-year-old woman with bilateral cruciate-retaining total knee arthroplasties (CR-TKAs) who sustained unilateral periprosthetic distal femur fractures above their CR-TKA and experienced knee instability secondary to an iatrogenic posterior-cruciate-ligament (posterior cruciate ligament [PCL]) injury from retrograde intramedullary nailing. Both patients recovered knee stability after undergoing revision surgery. Conclusion: Many CR-TKA designs have sufficient medial-lateral intercondylar distance to place a retrograde nail, femoral components with a relatively posterior transition from the trochlear groove to the intercondylar box will necessitate a nail starting point closer to the PCL origin. This may contribute to iatrogenic postoperative knee instability for patients with CR-TKA designs.
CREST‐2 Commitment to Rigorous Assessment of Carotid Stenting for Primary Prevention of Stroke
Edwards, Lloyd J. , Roubin, Gary S., Brott, Thomas G. , Lal, Brajesh K. , Edwards, Lloyd J. , Meschia, James F.

Stroke: Vascular and Interventional Neurology | April 5, 2024 | Volume: 4 | Issue: 3 | Pages: No page available

10.1161/svin.123.001227 | PMID 40630854 Get It

Background Rather than considering carotid stenting and endarterectomy to be rival procedures, they ought to be seen as complementary, with some patients more suited to one procedure over another. The respective patient populations best suited for optimal outcomes with stenting and endarterectomy differ substantially. Hence, the CREST‐2 (Carotid Revascularization, Endarterectomy Versus Stent Trial‐2) ( study was designed as 2 separate 2‐arm randomized trials run in parallel. One trial compares intensive medical management with and without stenting; the other, intensive medical management with and without endarterectomy. Each trial has a recruitment target of 1240 patients with ≥70% asymptomatic carotid stenosis, randomized 1:1 in each arm. To ensure patient safety and give stenting the best possible chance of demonstrating net benefits in stroke prevention, CREST‐2 adopted a rigorous procedure for evaluating, monitoring, and approving operators to enroll in the trial. The CREST‐2 Registry was established to allow for recent experience for applicant stent operators. Methods The CREST‐2 Registry is a prospective, multicenter, short‐term observational study of carotid stenting allowing use of multiple devices. Results The registry enrolled its first patient in September 2014, and as of October 2, 2023, a total of 9830 patients have been treated by 207 different stent operators from 103 different clinical centers. In this mixed cohort of asymptomatic (61.1% of the cohort) and symptomatic (38.9%) patients, the 30‐day stroke rate is 1.8% and the combined 30‐day stroke or death rate is 2.6%. At its peak in March 2016, the registry achieved an enrollment rate of 142 cases/month. As of October 20, 2023, a total of 104 patients remain to be enrolled in the CREST‐2 stenting trial. Conclusion The registry has facilitated assembly of a high‐performing team of stent operators for the CREST‐2 trial. With continued support of the many operators, we anticipate completing enrollment by the summer of 2024.
A survey of practice in the anesthetic management of adolescent idiopathic scoliosis spine fusion by the North American Pediatric Spine Anesthesiologists Collaborative
Gilbertson, Laura E. , Muhly, Wallis T. , Montana, Michael C. , Chidambaran, Vidya , Sadacharam, Kesavan , Wilder, Robert T., Whyte, Simon D. , Hifko, Alan, Frankville, David D., Investigators, North American Pediatric Spine Anesthesiologists, Whyte, Simon D , DiCindio, Sabina , Sponseller, Paul D. , Investigators, North American Pediatric Spine Anesthesiologists

Pediatric Anesthesia | April 5, 2024 | Volume: 34 | Issue: 7 | Pages: 645-653

10.1111/pan.14895 | PMID 38578166 Get It

AbstractBackgroundAdolescent Idiopathic Scoliosis (AIS) affects 2%–4% of the general pediatric population. While surgical correction remains one of the most common orthopedic procedures performed in pediatrics, limited consensus exists on the perioperative anesthetic management.AimsTo examine the current state of anesthetic management of typical AIS spine fusions at institutions which have a dedicated pediatric orthopedic spine surgeon.MethodsA web‐based survey was sent to all members of the North American Pediatric Spine Anesthesiologists (NAPSA) Collaborative. This group included 34 anesthesiologists at 19 different institutions, each of whom has a Harms Study Group surgeon performing spine fusions at their hospital.ResultsThirty‐one of 34 (91.2%) anesthesiologists completed the survey, with a missing response rate from 0% to 16.1% depending on the question. Most anesthesia practices (77.4%; 95% confidence interval [CI], 67.7–93.4) do not have patients come for a preoperative visit prior to the day of surgery. Intravenous induction was the preferred method (74.2%; 95% CI 61.3–89.9), with the majority utilizing two peripheral IVs (93.5%; 95% CI 90.3–100) and an arterial line (100%; 95% CI 88.8–100). Paralytic administration for intubation and/or exposure was divided (51.6% rocuronium/vecuronium, 45.2% no paralytic, and 3.2% succinylcholine) amongst respondents. While tranexamic acid was consistently utilized for reducing blood loss, dosing regimens varied. When faced with neuromonitoring signal issues, 67.7% employ a formal protocol. Most anesthesiologists (93.5%; 95% CI 78.6–99.2) extubate immediately postoperatively with patients admitted to an inpatient floor bed (77.4%; 95% CI 67.7–93.3).ConclusionMost anesthesiologists (87.1%; 95% CI 80.6–99.9) report the use of some form of an anesthesia‐based protocol for AIS fusions, but our survey results show there is considerable variation in all aspects of perioperative care. Areas of agreement on management comprise the typical vascular access required, utilization of tranexamic acid, immediate extubation, and disposition to a floor bed. By recognizing the diversity of anesthetic care, we can develop areas of research and improve the perioperative management of AIS.
Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy
García‐Cordero, Indira , Anastassiadis, Chloe , Khoja, Abeer , Morales‐Rivero, Alonso , Thapa, Simrika, Vasilevskaya, Anna , Davenport, Carly, Sumra, Vishaal , Couto, Blas , Multani, Namita, Anor, Cassandra Jessica, Misquitta, Karen , Heuer, Hilary W. , Tang‐Wai, David F. , Dickerson, Bradford, Ljubenkov, Peter A. , Huey, Edward D. , Kovács, Gábor G. , Boxer, Adam L. , Taghdiri, Foad , Tartaglia, Maria Carmela , Kovacs, Gabor G , VandeVrede, Lawren , Pantelyat, Alexander , Litvan, Irene , Boeve, Bradley F. , Rojas, Julio C. , Fox, Susan H. , Lang, Anthony E.

Annals of Neurology | April 5, 2024 | Volume: 96 | Issue: 1 | Pages: 99-109

10.1002/ana.26930 | PMID 38578117 Get It

ObjectivesTo evaluate the effect of Alzheimer's disease (AD) ‐related biomarker change on clinical features, brain atrophy and functional connectivity of patients with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP).MethodsData from patients with a clinical diagnosis of CBS, PSP, and AD and healthy controls were obtained from the 4‐R‐Tauopathy Neuroimaging Initiative 1 and 2, the Alzheimer's Disease Neuroimaging Initiative, and a local cohort from the Toronto Western Hospital. Patients with CBS and PSP were divided into AD‐positive (CBS/PSP‐AD) and AD‐negative (CBS/PSP‐noAD) groups based on fluid biomarkers and amyloid PET scans. Cognitive, motor, and depression scores; AD fluid biomarkers (cerebrospinal p‐tau, t‐tau, and amyloid‐beta, and plasma ptau‐217); and neuroimaging data (amyloid PET, MRI and fMRI) were collected. Clinical features, whole‐brain gray matter volume and functional networks connectivity were compared across groups.ResultsData were analyzed from 87 CBS/PSP‐noAD and 23 CBS/PSP‐AD, 18 AD, and 30 healthy controls. CBS/PSP‐noAD showed worse performance in comparison to CBS/PSP‐AD in the PSPRS [mean(SD): 34.8(15.8) vs 23.3(11.6)] and the UPDRS scores [mean(SD): 34.2(17.0) vs 21.8(13.3)]. CBS/PSP‐AD demonstrated atrophy in AD signature areas and brainstem, while CBS/PSP‐noAD patients displayed atrophy in frontal and temporal areas, globus pallidus, and brainstem compared to healthy controls. The default mode network showed greatest disconnection in CBS/PSP‐AD compared with CBS/PSP‐no AD and controls. The thalamic network connectivity was most affected in CBS/PSP‐noAD.InterpretationAD biomarker positivity may modulate the clinical presentation of CBS/PSP, with evidence of distinctive structural and functional brain changes associated with the AD pathology/co‐pathology. ANN NEUROL 2024;96:99–109
5-Year Follow-Up of a Physician Performance Feedback Report Intervention to Reduce Overuse and Excess Cost: A National Cohort Study
Walsh, Christi, Stasko, Thomas, Vidimos, Allison T. , Leshin, Barry, Billingsley, Elizabeth M. , Coldiron, Brett M., Bennett, Richard G. , Marks, Victor J., Otley, Clark C. , Rogers, Howard W., Goldman, Glenn D., Albertini, John G., Makary, Martin A. , Dun, Chen , Hicks, Caitlin W.

Dermatologic Surgery | April 5, 2024 | Volume: 50 | Issue: 6 | Pages: 558-564

10.1097/dss.0000000000004165 | PMID 38578837 Get It

BACKGROUND Mohs micrographic surgery efficiently treats skin cancer through staged resection, but surgeons' varying resection rates may lead to higher medical costs. OBJECTIVE To evaluate the cost savings associated with a quality improvement. MATERIALS AND METHODS The authors conducted a retrospective cohort study using 100% Medicare fee-for-service claims data to identify the change of mean stages per case for head/neck (HN) and trunk/extremity (TE) lesions before and after the quality improvement intervention from 2016 to 2021. They evaluated surgeon-level change in mean stages per case between the intervention and control groups, as well as the cost savings to Medicare over the same time period. RESULTS A total of 2,014 surgeons performed Mohs procedures on HN lesions. Among outlier surgeons who were notified, 31 surgeons (94%) for HN and 24 surgeons (89%) for TE reduced their mean stages per case with a median reduction of 0.16 and 0.21 stages, respectively. Reductions were also observed among outlier surgeons who were not notified, reducing their mean stages per case by 0.1 and 0.15 stages, respectively. The associated total 5-year savings after the intervention was 92 million USD. CONCLUSION The implementation of this physician-led benchmarking model was associated with broad reductions of physician utilization and significant cost savings.